Notably, mutations in STK11 and KEAP1 genes markedly influence the prognosis of patients with advanced NSCLC, especially when they co-occur with KRAS mutations, offering substantial potential to improve patient stratification for immunotherapy and thereby enhance clinical outcomes [163]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.